NCT06095674CompletedPhase 1
ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) study: safety, toxicity and immunological effects of peritumorally delivered immunotherapy in early-stage cervical cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 16 Dec 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 7 Nov 2023
- Start date
- 15 Oct 2024
- Lead sponsor
- Amsterdam UMC
- Diseases
- Cervical cancer
- NCT number
- NCT06095674
- EU CT number
- 2023-505968-11-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.